The antimicrobial protection hypothesis of Alzheimer's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review and theoretical model without new human or empirical data
PubMed 30314800 · doi:10.1016/j.jalz.2018.06.3040
What was done
The authors synthesized existing literature across genetic, experimental, and epidemiological studies to formulate a theoretical model termed the "Antimicrobial Protection Hypothesis" for Alzheimer's disease (AD). This is a narrative review and perspective paper containing no primary empirical study or clinical trial.
What was found
The abstract reports no numerical data or effect sizes. It proposes that amyloid-beta (Abeta) is an evolutionary conserved effector molecule of innate immunity that oligomerizes to entrap and neutralize invading pathogens. When immunochallenge or microbial burden is chronic, persistent Abeta fibrillization and immune pathway activation lead to sustained neuroinflammation and neurodegeneration.
Why it matters
The model provides a conceptual bridge between the amyloid cascade hypothesis and infectious/inflammatory models of Alzheimer's disease, reframing Abeta oligomerization as a dysregulated innate immune defense rather than a purely accidental, nonphysiological protein misfolding event.
Limits
As a conceptual narrative review, the paper provides no new empirical measurements, statistical tests, or clinical data. The abstract does not specify causal pathogen species, human cohort characteristics, or quantitative biomarkers validating the proposed entrapment mechanism in living patients.
Cited by
- supports Rudy Tanzi's research demonstrated that microbes, viruses, and bacteria from the microbiome are present in brain biopsies of Alzheimer's patients, triggering amyloid plaque deposition as an immune response.